Bioventus Inc. (BVS) trades at a trailing P/E of 26.2, forward P/E of 13.2. Trailing earnings yield is 3.82%, forward earnings yield 7.57%. PEG 0.10 (Peter Lynch undervalued ≤1.0). Graham Number is $5.13.
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -60.8 | 1.13 | 0.00 | 3.98 | - |
| 2017 | -666.0 | 7.32 | 0.00 | 3.74 | - |
| 2018 | -89.4 | -0.13 | 7.51 | 3.42 | 0.72% |
| 2019 | 159.3 | -1.03 | 7.63 | 3.21 | 0.84% |
| 2020 | 44.1 | 0.17 | 5.09 | 2.25 | 2.75% |
| 2021 | 34.0 | -0.25 | 1.44 | 1.53 | 0.06% |
| 2022 | -1.0 | 0.00 | 0.49 | 0.31 | - |
| 2023 | -2.1 | 0.55 | 1.90 | 0.64 | - |
| 2024 | -20.5 | 0.26 | 4.64 | 1.20 | - |
| 2025 | 21.8 | -0.13 | 2.69 | 0.87 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.32 | $274.5M | $-17.95M | -6.5% |
| 2017 | $-0.03 | $292.06M | $-1.64M | -0.6% |
| 2018 | $-0.22 | $319.18M | $-12.21M | -3.8% |
| 2019 | $0.12 | $340.14M | $6.85M | 2% |
| 2020 | $0.44 | $321.16M | $16.41M | 5.1% |
| 2021 | $-0.15 | $430.9M | $19.38M | 4.5% |
| 2022 | $-2.59 | $512.12M | $-158.7M | -31% |
| 2023 | $-2.49 | $512.35M | $-156.23M | -30.5% |
| 2024 | $-0.75 | $573.28M | $-33.54M | -5.9% |
| 2025 | $0.33 | $568.09M | $22.73M | 4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.75 | $0.55 – $0.86 | $604.75M | $602.8M – $606.69M | 3 |
| 2027 | $0.88 | $0.85 – $0.90 | $647.43M | $639.57M – $655.28M | 3 |
| 2028 | $1.02 | $0.88 – $1.16 | $687.21M | $687.2M – $687.22M | 2 |
| 2029 | $1.08 | $1.07 – $1.09 | $738.77M | $733.18M – $744.76M | 1 |
| 2030 | $1.22 | $1.21 – $1.23 | $794.93M | $788.92M – $801.39M | 1 |
